iTeos Therapeutics (ITOS) announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company’s audit committee. DeSimone is recognized for her role as President of U.S. Oncology at Merck & Co (MRK), where she established the company’s oncology division, growing it from less than $500 million in annual revenue to $9 billion in eight years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITOS:
- iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
- iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
- iTeos to Participate in Upcoming Investor Conferences
- iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones